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Introduction: Since 1996 Brazil has provided universal access to free antiretroviral therapy,
and  as a consequence, HIV/AIDS patients’ survival rate has improved dramatically. However,
according to scientiﬁc reports, a signiﬁcant number of patients are still late presenting for
HIV  treatment, which leads to consequences both for the individual and society. Clinical and
immunological characteristics of HIV patients newly diagnosed were accessed and factors
associated with late presentation for treatment were evaluated.
Methods: A cross-sectional study was carried out in an HIV/AIDS reference center in Belo
Horizonte, Minas Gerais, in Southeastern Brazil from 2008 to 2010. Operationally, patients
with  late presentation (LP) for treatment were those whose ﬁrst CD4 cell count was less
than  350 cells/mm3 or presented an AIDS deﬁning opportunistic infection. Patients with
late  presentation with advanced disease (LPAD) were those whose ﬁrst CD4 cell count was
less  than 200 cells/mm3 or presented an AIDS deﬁning opportunistic infection. LP and LPAD
associated risk factors were evaluated using logistic regression methods.
Results: Five hundred and twenty patients were included in the analysis. The median CD4
cell  count was 336 cells/mm3 (IQR: 130–531). Two hundred and seventy-nine patients (53.7%)
were classiﬁed as LP and 193 (37.1%) as LPAD. On average, 75% of the patients presented with
a  viral load (VL) >10,000 copies/ml. In multivariate logistic regression analysis the factors
associated with LP and LPAD were age, being symptomatic at ﬁrst visit and VL. Race was a
factor associated with LP but not with LPAD.
Conclusion: The proportion of patients who were late attending a clinic for HIV treatment isstill high, and effective str
vulnerable population are
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.ategies to improve early HIV detection with a special focus on the
 urgently needed.
© 2015 Elsevier Editora Ltda. All rights reserved.
i s . 2 0254  b r a z j i n f e c t d 
Introduction
Since the early 1980s, after the ﬁrst cases of infection
by HIV were reported in Brazil, the Brazilian government
response to the epidemic was forceful. It was based on early
diagnosis, treatment and prevention, which were supported
by participation from civil society and respect for human
rights.1
In 1996 Brazil became the ﬁrst developing country to ensure
universal access to free antiretroviral therapy (ARV) guaran-
teed by the Federal Law 9313. Consequently, the survival rate
among Brazilian AIDS patients has improved dramatically.2
In spite of preventive efforts and actions to early diagnose
the infection, many  patients are still late presenting for
treatment.3–10,11
It is estimated that there has been a decrease in the propor-
tion of patients who  present late for treatment in Brazil over
recent years. According to surveillance data reports 29% of
patients presented with CD4 cell count less than 200 cell/mm3
and at least half of patients presented with a CD4 cell count
less than 350 cell/mm3 in 2012.11
It is difﬁcult to compare the proportion of late diag-
nosis of HIV infection in different countries and even the
trends over the years in a given country, since there are
more than 20 criteria for this deﬁnition.12,13,14 This seems
to be a worldwide problem. A recent meta-analysis of 44
studies in developed countries showed that the average CD4
cell count in the ﬁrst visit for treatment has not increased
meaningfully in the past 20 years and the majority of peo-
ple still present with CD4 cell count less than 350 cells/mm3.
15
Late diagnosis and thus delayed treatment may impact
on the individual as well as on the society. Patients
who  start ARV with low CD4 cell count present higher
morbidity and mortality and have poorer treatment
response.13
The impact for society is that the treatment for late diag-
nosis increases costs for the health system in the short and
long runs.16 In addition, those who present for treatment with
more advanced disease have higher probability of transmis-
sion since they do not know about their infection and cannot
adopt risk reduction precautions or lower their viral load as a
consequence of ARV therapy.17
A better understanding of local data and the factors associ-
ated with patients late presenting for treatment are important.
These could help ensuring public surveillance programs and
to provide targeted intervention, focusing on individuals who
are particularly at risk.
The objective of this study was to describe the social, demo-
graphic, clinical and immunological characteristics of patients
recently diagnosed with HIV infection in a reference center for
HIV/AIDS – Voluntary Counseling and Testing Site/Specialized
Center in HIV Outclinic Patient Care (CTA/SAE) – in Belo Hori-
zonte, Minas Gerais state, Brazil, from 2008 to 2010, and to
determine factors associated with patients presenting late for
HIV treatment. 1 5;1  9(3):253–262
Materials  and  methods
Subjects  and  settings
All patients who presented for the ﬁrst time at CTA–SAE with
a recent HIV diagnosis between January 1, 2008 and December
31 2010 were included.
Belo Horizonte is one of the most populated metropolitan
areas in the country and is the capital city of Minas Gerais,
a state in southeast Brazil. The HIV detection rates in the
city are decreasing: in June 2013 it was 27.2 cases/100,000
inhabitants.11 Between 2002, when the service was imple-
mented, and 2014, about 3300 patients have been registered at
CTA–SAE, of which 2398 (72.7%) are currently using ARV. It is
one of the three main clinics that provide HIV treatment in the
Belo Horizonte metropolitan area, providing care for almost
20% of newly diagnosed HIV patients in the city.
Patients were eligible for the study if they were over 18 years
old; had had a recent diagnosis of the HIV infection (deﬁned
as those who had been diagnosed in the previous 12 months);
had initiated treatment at CTA–SAE between the 1 January
2008 and 31 December 2010, and had had at least one CD4
cell count or an AIDS deﬁning opportunistic infection (CDC)
registered between the diagnosis and one year thereafter.18
To include only patients newly diagnosed with HIV infection,
several criteria were used to exclude patients who  might have
previously known about their HIV infection, or who  had a rou-
tine screening, as during pregnancy.
Patients were excluded if registered at CTA–SAE for more
than one year after the ﬁrst positive HIV test; had no doc-
umented date for their HIV test; those tested through a
pre-natal screening; and those who had attended another
HIV/AIDS specialized center. Only patients with at least two
visits to the center were included in the study. Ethical approval
was obtained from local ethical committees.
Study  design
A cross-sectional study of a historical cohort was carried out.
All data was retrieved from clinical charts using standard-
ized forms. Data abstracted from the charts were demographic
information, clinical features, laboratory data (HIV viral load,
CD4 cell counts, serology for syphilis, hepatitis B and C, and
tuberculin skin test result) and time on ARV if it had been
initiated after the ﬁrst appointment at the clinic.
Deﬁnitions  and  variables  of  interest
Late presenters (LP) were those patients whose ﬁrst CD4 cell
count was less than 350 cells/mm3 and had an AIDS deﬁn-
ing opportunistic infection were deﬁned as late presenters
(LP). Subjects who presented with a CD4 cell count less than
3200 cells/mm or had an AIDS deﬁning opportunistic infection
were deﬁned as late presenters with advanced disease (LPAD).
Consequently, those patients whose ﬁrst CD4 cell count was
equal to or higher than 350 cell/mm3 were classiﬁed as non
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ate presenters (NLP). This deﬁnition is in accordance with a
011 European Late Presenters Consensus Deﬁnition.19
The following exposure variables were considered: year of
IV diagnosis; age at the time of HIV diagnosis; date of the
rst attendance to the clinic; gender; race; level of education;
ccupation; place of residence; be part of a self-reported HIV
isk group; HIV viral load (VL); clinical features; reasons to be
ested for HIV; hepatitis B (HBsAg and HBc antibody) and C
erology (HCV antibody); syphilis (VDRL) and tuberculin skin
est (TST).
Patients were categorized by age of the patient at the
ime of HIV diagnosis using the median age, race as white
nd non-white, years of schooling no education (illiterate),
ewer than eight years, eight to eleven years, and more
han 11 years, occupation as housewife, retired, unemployed,
mployed, student and other, and place of residence as Belo
orizonte city, Belo Horizonte metropolitan area, or other
ities.
Only sexual exposure was considered as exposure risk cat-
gory (heterosexual men, heterosexual women, and men  who
ave sex with men  – MSM)  since there were only three patients
0.6%) of injecting drug users (IDU). The date of the ﬁrst HIV
est was considered as the date of HIV diagnosis. Patients
ere considered symptomatic if there were any symptom
escribed by the doctor in the clinical chart. Patients who
ere symptomatic at ﬁrst visit, without a deﬁning oppor-
unistic infection, pneumonia or chronic nonspeciﬁc diarrhea,
Total  patients admitted with HIV i
2008 to Decembe
N=811
Attended the clinic only once
N=41
Diagnosed with  HIV more than one
year before the first attendance to the clinic
N=31
Without date of diagnosis
N=3
N=520
Fig. 1 – Diagram of the eligibility of patients for analysis in5;1 9(3):253–262 255
were classiﬁed as patients with non-speciﬁc symptoms. The
reasons to be tested for HIV were categorized as: doctor
request, self request, testing in Voluntary Counseling and
Testing sites (VCT), and other.
Statistical  analyses
The categorical variables were expressed in terms of abso-
lute and relative frequencies, and numerical variables were
expressed as medians and interquartile ranges (IQR). Uni-
variate and multivariate analyses for factors associated to
LP and LPAD were performed. In univariate analysis, cate-
gorical data was compared using contingency tables and a
Chi-Square test; numerical variables were compared using the
Mann–Whitney U test. Multivariate analysis was conducted
using logistic regression models with backward manual elim-
ination of variables.
Candidate variables for multivariate analysis were those
that showed an association with LP and LPAD with a
p-value ≤ 0.20 in the univariate analysis. To estimate the mag-
nitude of the association between response variables and
LP/LPAD, odds ratio (OR) with 95% conﬁdence intervals (95% CI)
was used. All p-values less than 0.05 were considered statisti-
cally signiﬁcant. Goodness of ﬁt testing of logistic regression
was assessed by Hosmer–Lemeshow test. Statistical analy-
ses were performed with SPSS software version 21 (SPSS Inc.,
Chicago, IL, USA).
n the clinic from January 1st
r 31st 2010
Had prior treatment in another specialized
HIV service
N=205
Clinical charts not found
N=2
Diagnosed in pre-natal screening
N=9
 CTA–SAE. from 1 January 2008 to 31 December 2010.
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Table 1 – Characteristics of newly  diagnosed HIV
patients at initiation of treatment in CTA–SAE from 2008
to 2010.
Characteristics N = 520
Male n (%) 402 (77.3)
Age (y), median (IQR) 35.1 (28.1–44.6)
CD4 cell count, median (IQR) 336 (130–531)
LP, n (%) 279 (53.7)
LPAD, n (%) 193  (37.1)
Level of education, n (%)a
Illiterate 13 (2.5)
<8 y 147 (28.3)
8–11 y 230 (44.2)
>11 y 126 (24.2)
HIV Risk Exposure, n (%)
Heterosexual women 118 (22.7)
Heterosexual men 159 (30.6)
MSM 243 (46.7)
Occupation, n (%)b
Housewife 21 (4.0)
Retired 27 (5.2)
Unemployed 32 (6.2)
Employed 397 (76.3)
Student 30 (5.8)
Race, n (%)c
White 247 (47.5)
Non-white 236 (45.4)
Place of residence, n (%)
Belo Horizonte 404 (77.7)
Metropolitan area 93 (17.9)
Other 23 (4.4)
Reasons for the HIV test, n (%)
Doctor request 260 (50.0)
Patient request 84 (16.2)
Voluntary Counseling and
Testing sites
67  (12.9)
Other 109 (21.0)
Time between the diagnosis
and ﬁrst attendance (days),
median (IQR)
47  (28 –76.7)
Viral Load (copies/mL),
median (IQR)
30,597 (9672.5–108,901)
HBsAg positive, n (%)d 13 (2.5)
Anti-HBc positive, n (%)e 123 (23.7)
Anti-HCV positive, n (%)f 15 (2.9)
VDRL positive, n (%)g 81 (15.6)
Tuberculin skin test, n (%)h
Negative (<5 mm) 352 (67.7)
Positive (≥5 mm) 39 (7.5)
Attending with symptoms, n
(%)
238 (45.8)
Non-speciﬁc symptoms 184 (35.4)
Candida esophagitis 48 (9.2)
Chronic nonspeciﬁc
diarrhea
44  (8.5)
Pneumonia 30 (5.8)
Tuberculosis 20 (3.8)
Pneumocystis jiroveci
pneumonia
17  (3.3)
Toxoplasma gondii
encephalitis
14  (2.7)
Table 1 – (Continued)
Characteristics N = 520
Interval in days between ﬁrst
attendance and ARV
initiation, median (IQR)
57.5  (27.8–430)
Year of ﬁrst attendance, n (%)
2008 190 (36.5)
2009 183 (35.2)
2010 147 (28.3)
Abbreviation: IQR, interquartile range; LA, late presentation to care.
a Missing data: n = 4 (0.8%).
b Missing data: n = 13 (2.5%).
c Missing data: n = 37 (7.1%).
d Missing data:n = 19 (3.7%).
e Missing data:n = 65 (12.5%).
f Missing data:n = 16 (3.1%).
g Missing data:n = 11 (2.1%).
h Missing data:n = 129 (24.8%).
Results
A total of 811 HIV infected patients were admitted to the clinic
between January 1 2008 and December 31 2010. Five-hundred
and twenty patients were eligible for the analysis (Fig. 1).
The majority of patients included were men  (77. 3%) with
a median age of 35.1 years (IQR 28.1–44.6). The overall median
CD4 cell count was 336 cells/mm3 (IQR: 130–531). It was greater
among MSM (390 cells/mm3 IQR: 209–563) than in heterosex-
ual women (338 cells/mm3 IQR: 130–531) and heterosexual
men (225 cell/mm3 IQR: 58–444). Almost 70% of the patients
had had at least eight years of education (n = 356–68.4%).
At least 75% of them lived in Belo Horizonte city. Three-
hundred and ninety seven patients (76. 3%) were employed.
Two-hundred and forty-three patients (46.7%) self-reported as
MSM and 159 (30.6%) self-reported as heterosexual. From 483
patients who provided information about their racial status,
51% declared themselves as white and 49% as non-white. CD4
cell count was available for 519 patients (99.8%). Those who  did
not have a CD4 count measurement, presented with an AIDS
deﬁning opportunist infection. Viral load measurements at
ﬁrst visit were available for 97% of the patients. The median VL
for the whole cohort was 30,597 copies/ml (IQR: 9673–108,901).
HBsAg, anti-HbC and anti-HCV were positive in 13 (2.5%), 123
(23.7%) and 15 (2.9%) patients, respectively.
Two-hundred and seventy-nine patients (53.7%) were clas-
siﬁed as LP and 193 (37.1%) classiﬁed as LPAD. Despite having a
CD4 thresholds higher than 350 cell/mm3 and 200 cells/mm3,
eight and twenty patients met  the LP and LPAD criteria,
respectively, due to the diagnosis of an AIDS deﬁning oppor-
tunistic infection. The characteristics of the cohort are shown
in Table 1.
Table 2 shows the characteristics of the patients accord-
ing to their baseline CD4 cell count measurement. LP and
LPAD patients were signiﬁcantly older than NLP patients, had
a median age of 39.7 (IQR: 30.8–46.4), 41.2 (IQR: 33.9–47) and
31.8 (IQR: 25.8–41.5), respectively (p < 0.001). The proportion of
MSM among LP and LPAD was 38.4% and 34.2%, respectively,
whereas almost half of patients of the overall cohort and 56.4%
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Table 2 – Comparison of new HIV patients at initiation of treatment in CTA–SAE from 2008–2010 according to their
baseline CD4 cell count.
Characteristics NLP (n = 241; 46.3.1%) LP (n = 279; 53.7%) p-value¶ LPAD (n = 193; 37.1%) p-value§
Male, n (%) 186 (77.2) 216 (77.4) 0.948 149 (77.2) 0.916
Female, n % 55 (22.8) 63 (22.6) 43 (22.8)
Age (y), median (IQR) 31.8 (25.8–41.5) 39.7 (30.8–46.4) <0.001 41.2 (33.9–47.0) < 0.001
Age ≤35, n (%) 154 (63.9) 104 (37.3) <0.001 54 (28.0) < 0.001
Level of education, n (%)a <0.001 <  0.001
Illiterate 2 (0.8) 11 (4) 8  (4.1)
<8 y 49  (20.3) 98 (35.1) 79 (40.9)
8–11 y 108 (44.8) 122 (43.7) 75 (38.9)
>11 y 79 (32.8) 47 (16.8) 31 (16.1)
HIV risk exposure, n (%) <0.001 < 0.001
Heterosexual women 55 (22.8) 63 (22.6) 44 (22.8)
Heterosexual men 50 (20.8) 109 (39.1) 83 (43.0)
MSM 136 (56.4) 107 (38.4) 66 (34.2)
Occupation, n (%)b 0.047 0.012
Housewife 9 (3.7) 12 (4.3) 9 (4.7)
Retired 10 (4.1) 17 (6.1) 13 (6.7)
Unemployed 11 (4.6) 21 (7.5) 14 (7.3)
Employed 183 (75.9) 214 (76.7) 152 (78.8)
Student 21 (8.7) 9 (3.2) 3 (1.6)
Race, n (%)c 0.005 0.004
White 132 (54.8) 115 (41.2) 76 (39.4)
Non-white 96 (39.8) 140 (50.2) 99 (51.3)
Place of residence, n (%) 0.179 0.170
Belo Horizonte 192 (79.7) 212 (76.0) 153 (79.3)
Metropolitan area 43 (17.8) 50 (17.9) 28 (14.5)
Others 6 (2.5) 16 (5.7) 11 (5.7)
Reasons for HIV test, n (%) <0.001 <0.001
Doctor request 76 (31.5) 184 (66.0) 142 (73.6)
Patient request 56 (23.2) 28 (10.0) 19 (9.8)
Voluntary Counseling
and Testing sites
44  (18.3) 23 (8.2) 11 (5.7)
Others 64 (26.1) 44 (15.8) 21 (10.9)
Time between the
diagnosis and ﬁrst
attendance (days),
median (IQR)
54  (29.5–91.5) 41 (27–65) 0.005 40 (26–63.5) 0.004
Viral Load (copies/mL)
median (IQR)
15,600 (5314–29536) 81,742 (26799–271788) <0.001 116,180 (45463–353826) <0.001
HBsAg positive, n (%)d 3 (1.2) 10 (3.6) 0.099 8 (4.1) 0.069
Anti-HBc positive, n (%)e 48 (19.9) 75 (26.9) 0.060 58 (30.1) 0.018
Anti-HCV positive, n (%)f 3 (1.2) 12 (4.3) 0.062 9 (4.7) 0.039
VDRL positive, n (%)g 48 (19.9) 33 (11.8) 0.015 21 (10.9) 0.012
Tuberculin skin test, n (%)h 0.831 0.976
Negative (<5 mm) 162 (67.2) 190 (68.1) 130 (67.4)
Positive (≥5 mm) 23 (9.5) 16 (5.7) 10 (5.2)
Attend with symptoms, n
(%)
48 (19.9) 190 (68.1) <0.001 160 (82.9) <0.001
Interval in days between
ﬁrst attendance and
ARV initiation, median
(IQR)
584 (306–848) 35 (17–57) <0.001 28 (12–43) <0.001
Year of ﬁrst attendance, n
(%)
0.127  0.055
2008 77 (31.9) 113 (40.5) 83 (43.0)
2009 92 (38.2) 91 (32.6) 59 (30.6)
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Table 2 – (Continued)
Characteristics NLP (n = 241; 46.3.1%) LP (n = 279; 53.7%) p-value¶ LPAD (n = 193; 37.1%) p-value§
2010 72 (29.9) 75 (26.9) 51 (26.4)
Abbreviations: NLP, not late presentation; LP, late presentation to care; LPAD late presentation with advanced disease; IQR, interquartile range;
MSM, men who have sex with men; VCT, Voluntary Counseling and Testing sites.
a Missing data: n = 3 (1.2%) – NLP; n = 1 (0.4%) – LP; n = 0 – LPAD.
b Missing data: n = 7 (2.9%) – NLP; n = 6 (2.2%) – LP; N = 2 (1.0%) – LPAD.
c Missing data: n = 13 (5.4%) – NLP; n = 24 (8.6%) – LA; N = 18 (9.3%) – LPAD.
d Missing data: n = 11 (4.6%) – NLP; n = 8 (2.9) – LP; N = 4 (2.1) – LPAD.
e Missing data:n = 24 (9.9%) – NLP; n = 41 (14.7) – LP; N = 29 (15.0) – LPAD.
f Missing data:n = 10 (4.1%) – NLP; n = 6 (2.2) – LP; N = 5 (2.6) – LPAD.
g Missing data: n = 7 (2.9%) – NLP; n = 4 (1.4) – LP; N = 4 (2.1) – LPAD.
h Missing data: n = 56 (23.2%) – NLP; n = 73 (26.2) – LP; N = 53 (27.5) – LPAD.
¶ p-value comparing NLP to LP.
§ p-value comparing NLP to LPAD.
of NLP were MSM.  On the other hand, the proportion of hetero-
sexual men  was higher among LP and LPAD. The proportion
of patients with more  than 11 years of schooling in the NLP
group was twice the proportion among LP and LPAD groups.
Half of the patients in the cohort were tested for HIV
because a doctor advised them to do so and this proportion
increased in LP (66.0%) and LPAD (73.6%) groups and decreased
among NLP (31.5%).
The median VL was almost six and eight fold higher among
LP and LPAD, respectively, when compared to NLP. Co-infection
with hepatitis B was higher in LP and LPAD groups than among
NLP but without statistical signiﬁcance (p = 0.099 for LP and
p = 0.069 for LPAD). The proportion of positive HCV-antibody
was higher in LP and LPAD groups but without statistical sig-
niﬁcance for LP (p = 0.06).
The median time between the diagnosis and the ﬁrst visit
to the treatment center was shorter in LP and LPAD groups
than among NLP. The proportion of symptomatic patients at
ﬁrst visit was higher in LP (68.1%) and LPAD (82.9%) groups
than in NLP (19.9%) group. The most reported AIDS deﬁning
opportunistic infections in LP and LPAD groups were Candida
esophagitis (n = 48), Pneumocystis jiroveci pneumonia (n = 17),
Toxoplasma gondii encephalitis (n = 14) and tuberculosis (n = 20).
Non-AIDS deﬁning conditions included chronic nonspeciﬁc
diarrhea (n = 44), bacterial pneumonia (n = 24) and nonspeciﬁc
symptoms (n = 142). In NLP group 48 patients reported symp-
toms at ﬁrst visit; six had had a bacterial pneumonia and 42
nonspeciﬁc symptoms.
The results of univariate analysis using binary logistic
regression to identify factors associated to LP and LPAD are
shown in Table 3. Age over 35 years compared to those under
35; non-white compared to white; heterosexual men  com-
pared to HSH; high VL and being symptomatic at ﬁrst visit
compared to non-symptomatic patients were all associated
with LP or LPAD.
Being retired, unemployed, or employed were all associated
with LP and LPAD when compared to students. Being a house-
wife was associated to LPAD but not with LP. Protective factors
were having completed more  than eight years of schooling
compared to less than eight years, not having done the HIV test
because a doctor had requested and having a positive VDRL.
Starting care in 2009 compared to starting care in 2008 was
associated with less chance to be LPAD.The factors associated with LP in the ﬁnal multivariate
logistic regression model were age, race, reasons to be tested
for HIV, VL, symptoms at ﬁrst visit, time between HIV diagnosis
and the ﬁrst visit, and VDRL (Table 4). Similarly, the predic-
tive factors for LPAD were the same as for LP except race and
reason to be tested for HIV. Factors associated with less LP
were self request for being tested for HIV compared to doc-
tor’s request, and having a positive VDRL. Factors associated
with less LPAD were living in the metropolitan area compared
to living in Belo Horizonte, and having a positive VDRL. For A
shorter interval between the ﬁrst visit and ARV initiation were
associated with both LP and LPAD.
Discussion
The proportion of LP (53.7%) and LPAD (37.1%) found in this
study was signiﬁcantly elevated. These rates are high, espe-
cially in Brazil, where a well recognized public health AIDS
program is available for over 30 years.
These ﬁndings were higher than those reported by  the
Brazilian Health Ministry in recent years.11 Similar to other
studies in Belo Horizonte city, 70% of the LP started care with
CD4 cell count less than 200 cells/mm3.4,9 The LPAD in this
study was less frequent than reported previously in other
Brazilian studies which ranged from 40.8% to 61%.3,6
Compared to surveillance data for the whole HIV/AIDS
Brazilian population, there was a higher proportion of male
subjects as well as MSM in this cohort. Patients included in
this cohort had higher educational levels than reported for
the overall Brazilian population10,11 and for Belo Horizonte in
particular.4,9 The proportion of each race did not differ from
the national data.
In other limited-resource regions such as in African
countries, the proportion of LP and LPAD are higher than
that observed in this study with 70–80% presenting with
advanced disease and 50–60% with CD4 count less than
350 cells/mm3.20–22 In Mexico as well as in Africa the propor-
tion of LPAD was estimated to be 61%.23 The proportion of LP
was similar to data from 35 countries in Europe,24 the United
25States of America (USA) and Canada.
LP and LPAD patients were older and this is in accor-
dance with the literature.3,6,13,24–26 This population might have
lower risk perception and be less educated that the younger
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Table 3 – Univariate analysis of factors associated with LP and LPAD of new HIV patients who  initiate treatment in
CTA–SAE 2008–2010.
Variables LP LPAD
Odds ratio 95%IC p-value Odds ratio 95%IC p-value
Sex
Male 1.00 1.00
Female 0.99 0.65–1.49 0.948 1.01 0.66–1.54 0.965
Age (years)
<35 1.00 1.00
≥35 2.98 2.08–4.26 <0.001 4.27 2.90–6.28 <0.001
HIV risk exposure
Heterosexual women 1.46 0.94–2.26 0.095 1.59 1.00–2.55 0.051
Heterosexual men 2.77 1.82–4.22 <0.001 2.93 1.92–4.46 0.000
MSM 1.00 1.00
Level of education (years)
Illiterate 2.75 0.59–12.89 0.415 1.38 0.43–4.41 0.590
<8 1.00 1.00
8–11 0.56 0.37–0.87 0.009 0.42 0.27–0.64 <0.001
>11 0.30 0.18–0.49 <0.001 0.28 0.17–0.47 <0.001
Occupation
Housewife 3.11 0.97–9.97 0.056 6.75 1.55–29.45 0.011
Retired 3.97 1.31–11.97 0.014 8.36 2.04–34.29 0.003
Unemployed 4.45 1.53–12.97 0.006 7.00 1.76–27.89 0.006
Employed 2.73 1.22–6.11 0.015 5.58 1.67–18.72 0.005
Students 1.00 1.00
Race
White 1.00
Non-white 1.67 1.17–2.40 0.005 1.63 1.12–2.36 0.011
Place of residence
Belo Horizonte 1.00
Metropolitan area 1.05 0.67–1.65 0.823 0.71 0.42–1.15 0.162
Other cities 2.42 0.93–6.30 0.071 1.64 0.69–3.88 0.259
Reason for the HIV test
Doctor requirement 1.00 1.00
Patient requirement 0.21 0.12–0.35 <0.001 0.24 0.14–0.43 <0.001
VCT 0.22 0.12–0.38 <0.001 0.16 0.08–0.33 <0.001
Other 0.28 0.18–0.45 <0.001 0.20 0.12–0.34 <0.001
Time between the diagnosis
and the ﬁrst attendance (in
10 days)
0.97  0.94–1.00 0.040 0.97 0.94–1.01 0.117
VL (in 10,000 units/ml) 1.21 1.15–1.27 <0.001 1.10 1.07–1.12 <0.001
Symptoms at ﬁrst attendance
No 1.00
Yes 8.53 5.73–12.86 <0.001 15.48 9.84–24.34 <0.001
Time between the diagnosis
and the ﬁrst attendance and
ARV initiation (in 10 days)
0.96  0.95–0.97 <0.001 0.96 0.95–0.97 <0.001
Year of ﬁrst attendance
2008 1.00
2009 0.68 0.46–1.02 0.061 0.62 0.41–0.93 0.021
2010 0.70 0.45–1.10 0.122 0.69 0.44–1.09 0.112
VDRL
Negative 1.00 1.00
Positive 0.53 0.33–0.86 0.010 0.54 0.32–0.92 0.024
HbsAg
Negative 1.00 1.00
Positive 0.53 0.33–0.86 0.109 2.76 0.89–8.57 0.079
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Table 3 – (Continued)
Variables LP LPAD
Odds ratio 95%IC p-value Odds ratio 95%IC p-value
Anti-HCV
Negative 1.00 1.00
Positive 3.49 0.97–12.54 0.055 2.62 0.92–7.48 0.072
ith a
; ARVAbbreviations: LP, late presentation to care; LPAD, late presentation w
with men; VCT, Voluntary Counseling and Testing sites; VL, viral load
generations. Being over 35 years was associated with LP (OR:
1.81 95%IC 1.05–3.12, p = 0. 033) and LPAD (OR: 2.61 95%IC
1.49–4.58, p = 0. 001).
The proportion of positive TST in the entire cohort was
7.5%. Although the proportion of positive TST was higher in
the NLP group than in LP and LPAD groups there were no statis-
tical difference (p = 0.831 and p = 0.976, respectively). This could
be explained by the high proportion of missing TST results
(24.8%).
As shown in the Brazilian surveillance data, sexual trans-
mission is the main route of transmission as the IDU group
was minimal.11
Gender was not associated with LP and LPAD. How-
ever, among patients self-reported as heterosexual, women
Table 4 – Final Model of Multivariate Regression of factors asso
treatment in CTA–SAE 2008–2010.
Variables LPa
Odds ratio 95%IC 
Age (years)
<35 1.00 
≥35 1.81 1.05–3.12 
Race
White 1.00
Non-white 1.75 1.03–2.97 
Reasons for HIV test
Doctor request 1.00
Self request 0.44 0.20–0.97 
VCT 0.47 0.22–1.02 
Others 1.08 0.54–2.15 
Place of residence
Belo Horizonte 
Metropolitan area 
Other cities 
VL (in 10,000 units/ml) 1.18 1.11–1.25 
Symptoms at ﬁrst attendance
No 1.00 
Yes 4.23 2.32–7.69 
Time between the diagnoses and
the ﬁrst attendance and ARV
initiation (in 10 days)
0.96  0.95–0.97 
VDRL
Negative 1.00 
Positive 0.42 0.19–0.90 
Abbreviations: VCT, Voluntary Counseling and Testing sites; VL, viral load
a Hosmer–Lemeshow 2 = 9.97, DF = 8, p value 0.267.
b Hosmer–Lemeshow 2 = 7.47, DF = 8, p value 0.487.dvanced disease; IQR, interquartile range; MSM, men who have sex
, antiretroviral therapy; IC, interval of conﬁdence.
presented earlier than men. Sixty-eight percent of heterosex-
ual men  were LP versus 53% of heterosexual women. This
could be explained by the fact that Brazilian women take bet-
ter care of their health than men, and seek health services for
preventive exams more  frequently.27 Heterosexual exposure,
particularly among males, is widely correlated with late pre-
sentation and this could be explained by fewer opportunities
to be tested, as they are not the main target of campaigns
launched by the government as well as their own low risk
perception.12,13Compared to students, being retired, unemployed or
employed was associated with LP and LPAD in univariate anal-
ysis. Being a housewife was associated to LPAD but not with
LP. These associations did hold in multivariate analysis. A
ciates with LP an LPAD of new HIV patients who  initiate
LPADb
p-value Odds ratio 95%IC p-value
1.00
0.033 2.61 1.49–4.58 <0.001
0.037
0.043
0.057
0.828
1.00
0.35 0.17–0.72 0.005
0.79 0.22–2.87 0.717
<0.001 1.06 1.04–1.09 <0.001
1.00
<0.001 7.75 4.15–14.45 <0.001
<0.001 0.97 0.96–0.98 <0.001
1.00
0.03 0.42 0.19–0.93 0.03
; ARV, antiretroviral therapy; IC, interval of conﬁdence.
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ossible explanation is the lower median age of the students
23 years IQR: 22–29) as compared to the median age of the
ther groups. Furthermore, the proportion of MSM among the
tudents were expressive (83.3%).
MSM  presented earlier to care than heterosexual men,
ccording to univariate but not multivariate analyses, possibly
ecause on average heterosexual patients were older than the
SM  group. The median age of heterosexual women was 42
ears (IQR: 33–49), 39 (IQR: 33–47) for heterosexual men, and
0 (IQR: 25–38) for MSM  (p < 0.001). Even though MSM make up
alf the HIV infected population, they are infected at a lower
ge, perceive themselves at risk and get tested at an earlier
tage, HIV prevention for this group remains a challenge.
In this study, the rates of HBsAg, anti-HBc and anti-
CV positive were lower than those reported for HIV/AIDS
atients in Africa.20 However, these rates are four, six and
wo fold greater than the rates reported for the general Brazil-
an population.28 The fact that the hepatitis B virus has the
ame infection routes as HIV could explain this increased
roportion. Therefore, it is important to reinforce hepatitis B
accination in the population.
Non-whites was shown be at higher risk for LP in multi-
ariate analysis. However, it should be pointed out that the
ean educational level of non-whites was lower than in the
hite group. The proportion of non-whites with less than
ight years of education was 60.2% versus 24% in the white
roup (p < 0.001). This fact is possibly related to disparities in
ccess to health care, social economic conditions and access
o education.
Living in the Belo Horizonte metropolitan area was a factor
hat reduced LPAD in multivariate analysis possibly because
0% of this population had their HIV test done for other rea-
ons including blood donation. To be accepted, donors be
ealthy since they are screened by a doctor before the dona-
ion takes place.
It is difﬁcult to compare the interval between diagnosis and
reatment, since in many  studies, the ﬁrst CD4 cell measure-
ent is considered as the start of care. In this study a median
nterval of 47 days (IQR: 28–77) was found for the overall popu-
ation, which was lower among LP (41 days) and LPAD (40 days)
han in NLP group (54 days) and correlates with the severity of
he disease and the need to start ARV treatment immediately.
The proportion of patients who presented with clinical
ymptoms was high and it was associated with increased risk
f LP and LPAD in multivariate regression. It is important to
tress that 32% of LP and 18% of LPAD were asymptomatic
t presentation in spite of having a high level of immune
epletion. Therefore, it is important to reinforce CD4 cell mea-
urement after diagnosis, whether the patient is symptomatic
r not. Furthermore, a high proportion of patients had their
IV test done because of a doctor’s referral in LP and LPAD
roups. This must be analyzed with caution and could repre-
ent a low perception of risk and a low knowledge of the HIV
isease.
Similar results were found in a study from Rio de Janeiro
nd Baltimore,5 where 75% of the studied population started
reatment with VL > 10.000 copies/ml, which indicates a high
otential for HIV transmission. As the impact of ARV and the
ecrease in VL are convincingly demonstrated and its impact
n transmission is widely accepted29 the results of this study5;1 9(3):253–262 261
show the high risk of transmission by those subjects before
they are diagnosed. In this way, enthusiasm for HIV treatment
as a prevention measure to reduce transmission is unlikely to
be accomplished unless early diagnosis is improved.
These ﬁndings are also relevant in clinical settings. Many
guidelines30,31 have recommended ARV initiation at higher
CD4 cell counts, but this discussion is not applicable for the
majority of new HIV patients since they present for treatment
with CD4 thresholds below the recommended number.
A positive VDRL was associated with a lower chance
of presenting late for treatment. In fact a person with an
active symptomatic sexually transmitted disease (STD) might
request a health service where early HIV testing is offered.
It is noteworthy that 65% of the patients with positive VDRL
were in the group of MSM, which reinforces the importance
of prevention in this group. In this study only positive VDRL
was considered and syphilis was not classiﬁed in clinical
stages.
Although a lower risk of LP was noted in 2009 in univariate
analysis, this did not hold true in the multivariate analysis. In
fact, an increase in the median levels of CD4 cells was found
in 2009 (377 cell/mm3 – IQR: 151–572) and 2010 (371 cells/mm3
– IQR: 164–530) compared to 2008 (272 cell/mm3 – IQR: 91–489).
Nevertheless, the proportion of heterosexual males in 2008
was higher (36.8%) than in 2009 (29%) and 2010 (24.5%) and this
could be considered as a confounding factor. This difference
in the proportion of heterosexual men  in these years could not
be explained by the study.
This study has limitations. As a historical study from a
single HIV cohort, they may not be representative of other
national or international sites, though our analysis may
provide insights applicable to such settings. Medical records
with complete information were an important point of this
study. The quality of data collected has led to a very few miss-
ing values.
In summary the results show that despite the availability
of ARV free of charge in Brazil for more  than 15 years and mas-
sive media campaigns encouraging HIV testing in the country,
the proportion of patients starting treatment late is still high.
These results suggest that recommendation for earlier treat-
ment will have little impact in prevention unless effective
strategies to increase universal HIV testing are implemented.
Special focus should be placed on those who  are not perceived
to be or do not perceive themselves to be at risk for HIV infec-
tion, such as elderly people, non-whites, less educated people,
and heterosexual men.
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